Inducible, virus-free direct lineage reprogramming enhances scalable generation of human inner ear hair cell-like cells
Creators
Abstract
Mammalian inner ear sensory hair cells are highly sensitive to environmental stress and do not regenerate, making hearing loss progressive and permanent. The paucity and extreme inaccessibility of these cells hinder the development of regenerative and otoprotective strategies, Direct lineage reprogramming to generate large quantities of hair cell-like cells in vitro offers a promising approach to overcome these experimental bottlenecks. Previously, we identified four transcription factors—Six1, Atoh1, Pou4f3, and Gfi1 (SAPG)—capable of converting mouse embryonic fibroblasts, adult tail tip fibroblasts, and postnatal mouse supporting cells into induced hair cell-like cells through retroviral or lentiviral transduction (Menendez et al., 2020). Here, we developed a virus-free, inducible system using a stable human induced pluripotent stem (iPS) cell line carrying doxycycline-inducible SAPG. Our inducible system significantly increases reprogramming efficiency compared to retroviral methods, achieving a ∼19-fold greater conversion to a hair cell fate in half the time. Immunostaining, Western blot, and single-nucleus RNA-seq analyses confirm the expression of hair cell-specific markers and activation of hair cell gene networks in reprogrammed cells. The reprogrammed hair cells closely resemble developing fetal hair cells, as evidenced by comparison with a human fetal inner ear dataset. Electrophysiological analysis reveals that the induced hair cell-like cells exhibit diverse voltage-dependent ion currents, including robust, quick-activating, slowly inactivating currents characteristic of primary hair cells. This virus-free approach improves scalability, reproducibility, and the modeling of hair cell differentiation, offering significant potential for hair cell regenerative strategies and preclinical drug discovery targeting ototoxicity and otoprotection.
Copyright and License (English)
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Acknowledgement (English)
We thank Welly Makmura and Juan Llamas for laboratory maintenance and John Duc Nguyen, Shun-Yang Cheng, and Kari Koppitch for bioinformatics support. We also acknowledge Valerie Hsiao for technical assistance, Francis James for maintaining the bioinformatics server, and Mickey Huang and the Choi Family Therapeutic Screening for high-content imaging and data transfer.
Additionally, we acknowledge both past and present lab members—Ksenia Gnedeva, Talon Trecek, Xizi Wang, Haoze Yu, Tuo Shi, Leah Kim, and Tuba Ege—for their valuable scientific discussions.
Funding (English)
Department of Defense - W81XWH-22-1-1009
Principal Investigators: Neil Segil, Andrew Mcmahon, John Oghalai
California Institute for Regenerative Medicine (CIRM) - DISC2-10773
Principal Investigators: Neil Segil, Justin Ichida
National Institutes of Health (NIH) - R01DC015829
Principal Investigators: Neil Segil, Andrew Mcmahon
National Institutes of Health (NIH) - R01DC014832
Principal Investigator: Andrew Groves
Keck School of Medicine of USC
Principal Investigators: Neil Segil
Conflict of Interest (English)
Andrew P. McMahon serves as a consultant or scientific advisor to Novartis, eGENESIS, Trestle Biotherapeutics, and IVIVA Medical. These companies have no competing technology and are not involved in this research. The other authors declare no competing interests.
Files
      
        2025.02.20.639352v1.full.pdf
        
      
    
    
      
        Files
         (5.3 MB)
        
      
    
    | Name | Size | Download all | 
|---|---|---|
| 
            
            md5:f77264ef2e8d2897d003ec64fa222659
             | 
          5.3 MB | Preview Download | 
Additional details
Related works
- Is previous version of
 - Journal Article: 10.7554/eLife.106550.1 (DOI)
 
Funding
- United States Department of Defense
 - W81XWH-22-1-1009
 - California Institute for Regenerative Medicine
 - DISC2-10773
 - National Institutes of Health
 - R01DC015829
 - National Institutes of Health
 - R01DC014832
 - University of Southern California
 - Keck School of Medicine of USC